Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Document › Details

Molecular Health GmbH. (11/16/15). "Press Release: Molecular Health Raises €25 Million in Private Financing". Heidelberg & Boston, MA.

Organisations Organisation Molecular Health GmbH (MolecularHealth)
  Group Molecular Health (Group)
  Organisation 2 Dievini Hopp BioTech Holding GmbH & Co. KG
  Group HOPP Group (family of Dietmar Hopp)
Products Product healthcare informatics
  Product 2 venture capital
Index terms Index term Molecular Health–SEVERAL: investment, 201511 private financing round €25m led by existing investor Dievini
  Index term 2 Molecular Health–Hopp Group: investment, 201511 private financing round totalling €25m led by existing investor Dievini
Persons Person Völker, Lutz (Molecular Health 201511 CEO)
  Person 2 von Bohlen, Friedrich (Dievini before Lion Bioscience)

Proceeds to further build commercial infrastructure and drive product adoption

Molecular Health, a leader in cloud-based healthcare decision support technology to enable evidence-based treatment decisions and improved outcomes, today announced that it has raised €25 million in private financing to expand commercial adoption of its healthcare decision engine. The round was led by current investor dievini, an investor in global life and health sciences companies. With the completion of this round of financing, Molecular Health has raised a total of approximately €100 million.

“Big data is largely driving decision-making for today’s physicians, diagnostic labs, and pharmaceutical companies. However, the sheer volume of data that exists today and its continuous, rapid expansion makes it increasingly complicated to digest and apply in a practical way,” said Lutz Voelker, Chief Executive Officer of Molecular Health. “Our platform integrates these data into the most comprehensive biomedical data warehouse in the world and quickly interprets information to generate accurate and actionable insights that drive important healthcare decisions, leading to both personalized treatment and more efficient therapy development. We greatly appreciate the continued support of dievini and look forward to expanding the company’s commercial infrastructure and driving adoption of our solutions.”

“Medicine is in one of its biggest changes ever, as molecular data and information are becoming the new currency in healthcare,” said Friedrich von Bohlen, Chairman of the Board of Directors and Managing Director of dievini. “We recognized long ago that Molecular Health was one of the most forward-thinking organizations in healthcare, with the unique potential to improve outcomes and health through the power of integrative computing and IT-based interpretation. We are excited to expand our support of Molecular Health, who are at the forefront of modern medicine, helping people in healthcare organizations improve understanding, interpretation and decision making.”

About Molecular Health

Molecular Health is a leading biomedical company that is transforming molecular data and medical knowledge into actionable clinical information for more efficient and safe targeted therapies for each individual patient. Molecular Health generates individualized analysis and clinical interpretation for evidence-based targeted therapy identification utilizing published medical knowledge in a clinical context. In Europe, Molecular Health has the first registered medical device of its kind for personalized cancer medicine. Molecular Health Inc., headquartered in Boston, MA, with a laboratory and support center in Greater Houston, TX, is a wholly owned subsidiary of Molecular Health GmbH, headquartered in Heidelberg, Germany. To learn more, please visit:


Mark Rodgers
+1 832-247-3068

Carla Mertens
+49 6221 43851-2275

Record changed: 2017-04-02


Picture [LSUK] – The Business Web Portal 600x80px

More documents for Molecular Health (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px

» top